share_log

愛帝宮：按於記錄日期 每持有三(3)股現有股份 獲發一(1)股供股股份之基準 進行供股之結果 及可轉換優先股之調整

AIDIGONG: RESULTS OF THE RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY THREE (3) EXISTING SHARES HELD ON RECORD DATE AND ADJUSTMENTS TO THE CONVERTIBLE PREFERENCE SHARES

Hong Kong Stock Exchange ·  May 13 07:15
Summary by Moomoo AI
愛帝宫母嬰健康股份有限公司（「愛帝宫」）宣布，其供股結果顯示於2024年5月6日的最後接納時限時，供股股份獲得超額認購，有效接納及申請總數為3,663,812,035股，相當於可供認購的1,478,338,324股供股股份總數約247.83%。其中，暫定配額通知書項下有效接納為1,234,078,384股，額外申請表格項下有效申請為2,429,733,651股，超額認購股份為2,185,473,711股。由於額外供股股份的有效申請數目遠超可供認購的數量，因此按照約10.05%的比例分配給合資格股東。包銷協議已於2024年5月7日成為無條件，供股所籌集的款項淨額約為56.30百萬港元，將按照供股章程所披露的方式使用。供股股份預計於2024年5月16日開始於聯交所買賣。此外，公司的A類及B類可轉換優先股換股價已調整，將額外發行113,147,266股股份。
愛帝宫母嬰健康股份有限公司（「愛帝宫」）宣布，其供股結果顯示於2024年5月6日的最後接納時限時，供股股份獲得超額認購，有效接納及申請總數為3,663,812,035股，相當於可供認購的1,478,338,324股供股股份總數約247.83%。其中，暫定配額通知書項下有效接納為1,234,078,384股，額外申請表格項下有效申請為2,429,733,651股，超額認購股份為2,185,473,711股。由於額外供股股份的有效申請數目遠超可供認購的數量，因此按照約10.05%的比例分配給合資格股東。包銷協議已於2024年5月7日成為無條件，供股所籌集的款項淨額約為56.30百萬港元，將按照供股章程所披露的方式使用。供股股份預計於2024年5月16日開始於聯交所買賣。此外，公司的A類及B類可轉換優先股換股價已調整，將額外發行113,147,266股股份。
AIDEMIO MATERNAL AND INFANT HEALTH CO., LTD. (“AIDOMIO”) ANNOUNCES THAT ITS SHARE OFFERING RESULTS SHOW THAT THE MAXIMUM NUMBER OF SHARES IS 3,663,812,035 SHARES, CORRESPONDING TO 1,478,338,324 SHARES AVAILABLE FOR SUBSCRIPTION BY THE FINAL ACCEPTANCE DEADLINE OF MAY 6, 2024. The total is about 247.83%. Of these, 1,234,078,384 shares are valid under the provisional quota notice, 2,429,733,651 shares are valid under the supplementary application form, and the oversubscribed share is 2,185,473,711 shares. Since the number of valid applications for additional shares far exceeds the number available for subscription, it is allocated to eligible shareholders at a ratio of approximately 10.05%. THE OUTSOURCING AGREEMENT BECAME UNCONDITIONAL ON 7 MAY 2024 AND THE NET PROCEEDS RAISED FOR SHARES OF APPROXIMATELY HK$56.30 MILLION WILL BE USED AS DISCLOSED IN THE SHARE PLAN. The shares are expected to start trading on the exchange on 16 May 2024. In addition, the Company's Class A and Class B Convertible Preferred Stock Exchange Price has been adjusted to issue an additional 113,147,266 shares.
AIDEMIO MATERNAL AND INFANT HEALTH CO., LTD. (“AIDOMIO”) ANNOUNCES THAT ITS SHARE OFFERING RESULTS SHOW THAT THE MAXIMUM NUMBER OF SHARES IS 3,663,812,035 SHARES, CORRESPONDING TO 1,478,338,324 SHARES AVAILABLE FOR SUBSCRIPTION BY THE FINAL ACCEPTANCE DEADLINE OF MAY 6, 2024. The total is about 247.83%. Of these, 1,234,078,384 shares are valid under the provisional quota notice, 2,429,733,651 shares are valid under the supplementary application form, and the oversubscribed share is 2,185,473,711 shares. Since the number of valid applications for additional shares far exceeds the number available for subscription, it is allocated to eligible shareholders at a ratio of approximately 10.05%. THE OUTSOURCING AGREEMENT BECAME UNCONDITIONAL ON 7 MAY 2024 AND THE NET PROCEEDS RAISED FOR SHARES OF APPROXIMATELY HK$56.30 MILLION WILL BE USED AS DISCLOSED IN THE SHARE PLAN. The shares are expected to start trading on the exchange on 16 May 2024. In addition, the Company's Class A and Class B Convertible Preferred Stock Exchange Price has been adjusted to issue an additional 113,147,266 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more